Skip to content
CancerIndex

Publication

Glypican-3-Targeted Paired Radiotheranostics in Orthotopic Liver Cancer Models.

Woonghee Lee, Joon-Yong Chung, Stephen Adler, Falguni Basuli, Kwamena Baidoo, Jianfeng Shi, Yuki Ueda, Satoshi Omiya, Divya Nambiar, Hima Makala, Julia Sheehan-Klenk, Stanley Fayn, Colleen P Olkowski, A Paden King, Benjamin Ruf, Tim F Greten, Orit Jacobson, Peter L Choyke, Freddy E Escorcia

Clinical cancer research : an official journal of the American Association for Cancer ResearchSep 9, 2026PMID 42714869doi:10.1158/1078-0432.CCR-26-1613 Journal ArticlepubmedProvenance
Source
PubMed
Retrieved
Sep 18, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260918-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

PURPOSE: Glypican-3 (GPC3), highly expressed in the most common liver cancer hepatocellular carcinoma (HCC) but absent from normal liver, represents an attractive tumor-selective target. We evaluated GPC3-targeted paired PET diagnostic and alpha particle therapeutic (radiotheranostic) agents in…

Read on PubMed

Linked entities

Linked entities (1)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Candidate 1

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.